Sahajanand Medical Technologies Limited IPO Details
MainboardListed
EQGMP TodayLive
₹17(+4.9%)
Est. Listing: ₹361
7-Day Trend
7 days ago: ₹12Latest: ₹17
Price Band₹327 - ₹344Lot: 43 Shares
Min Outlay₹14,061Retail Category
Closes On19 Oct 2026Bidding Deadline
Total Demand14.21xSubscription Book
Sahajanand Medical Technologies Limited IPO DetailsCore Specs
IPO Bidding Dates | 15 Oct 2026 to 19 Oct 2026 |
Allotment Date | 21 Oct 2026 |
Listing Date | 23 Oct 2026 |
Issue Price Band | ₹327 - ₹344 |
Market Lot Size | 43 Shares |
Face Value | ₹1 per share |
Total Issue Size | 1,38,22,116 Shares (₹475.48 Cr) |
Fresh Issue | - |
Offer For Sale (OFS) | 1,38,22,116 Shares (₹475.48 Cr) |
Listing Exchange(s) | NSE, BSE |
Pre-Issue Shares | 10,14,03,232 |
Post-Issue Shares | 10,14,03,232 |
Lot(s) Distribution
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 43 | ₹14,792 |
| sHNI (Min) | 14 | 602 | ₹2,07,088 |
| bHNI (Min) | 68 | 2,924 | ₹10,05,856 |
Company Financials (In Crores)
| Period Ended | Jun-26 | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|---|
| Assets | 1,309.00 | 1,276.43 | 1,094.90 | 970.58 |
| Revenue | 354.33 | 1,218.73 | 1,035.96 | 908.59 |
| Net Worth | 709.37 | 695.46 | 565.73 | 540.09 |
| Borrowing | 320.63 | 269.53 | 224.96 | 175.27 |
| PAT | 15.09 | 69.08 | 25.15 | -7.35 |
| Reserves | 699.56 | 685.65 | 555.97 | 530.34 |
Key Performance Indicators (KPI)
| Metric | Jun-26 | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|---|
| ROCE (%) | 3.16 | 11.57 | 10.37 | 8.05 |
| RONW (%) | 2.31 | 10.60 | 3.73 | -2.43 |
| EPS (₹) | 1.48 | 6.67 | 2.09 | -1.31 |
| P/E Ratio | 57.94 | 51.57 | - | - |
About Sahajanand Medical Technologies Limited
Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company that focuses on advanced Class III and Class C/D devices used mainly in vascular and structural heart treatments. The company was the first in the world to receive CE certification for a drug-eluting stent with a biodegradable polymer called Infinnium. Its product range includes coronary stents and balloons for vascular interventions, technologies like TAVI and occluders for structural heart treatments, as well as renal stents and drug-coated balloons. The company operates R&D centres in India and Thailand and has a strong innovation base with over 100 granted patents and several pending applications. Its key products, including Supraflex Cruz, Hydra, and Cocoon, are supported by multiple clinical studies and are used in more than 76 countries. Sahajanand follows a global distribution strategy combining direct sales, hybrid models, and distributor partnerships across different markets. As of March 31, 2025, the company had over 1,400 employees along with consultants and contract staff supporting its operations.
Strengths & Growth Drivers
- Advanced & Technologically Sophisticated Products: The Company is among a select group of global Class III (and Class C/D) players offering advanced cardiovascular implants, including DES, PTCA balloons, TAVI systems and Occluders. Its products are supported by clinical evidence and comply with stringent domestic and international regulatory standards.
- Strong Research & Development Capabilities: The Company operates two R&D facilities in India and Thailand, supported by 156 professionals. It holds over 119 patents granted globally, with 78 applications pending, supporting ongoing innovation in products such as its proprietary LDZ link and patented AVDC system.
- Strong Market Position in India & Overseas: The Company held nearly 25% market share by DES sales volume in India in FY2026. It also ranked among the top five companies by DES sales volume in Germany, Spain, Poland and Brazil, and by Occluder sales volume in Thailand, South Korea and India.
Risk Factors
- Strict Regulatory Compliance Requirements: The Company operates under stringent regulations across multiple markets, including India’s Drugs and Cosmetics Act and the EU Medical Device Regulation. Delays in approvals, adverse regulatory actions or failure to maintain required certifications could restrict product sales and negatively affect business prospects.
- Manufacturing & Operational Risks: The Company’s three manufacturing facilities may face quality control issues, operational disruptions, outdated machinery or underutilised capacity. These challenges could increase production costs, interrupt operations and adversely affect product quality, sales and reputation.
- Dependence on Key Raw Material Suppliers: The top 10 suppliers accounted for 63.61%, 59.15%, 64.37% and 58.88% of total purchases in the three months ended June 30, 2026 and FY2026, FY2025 and FY2024, respectively. Reliance on a limited number of suppliers, or a single supplier for certain critical materials, exposes the Company to supply disruptions and price fluctuations.
Company Promoters
- Bhargav Dhirajlal Kotadia
- Dhirajlal Vallabhbhai Kotadia
- Priyanka Dhirajlal Cohen
- Shree Hari Trust
Lead Manager(s)
Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, Hsbc Securities & Capital Markets Private Limited, Nuvama Wealth Management Limited
Current GMP Today+₹17Live Unofficial Premium
Estimated Listing Price₹14809.00Cap Price (₹14792) + GMP (₹17)
Estimated Listing Gain+0.1%Expected ROI per Share
Sahajanand Medical Technologies Limited Daily GMP Trend HistoryLive Daily Trend
| GMP Date | IPO Price | GMP (₹) | Est. Listing Price | Expected Gain (%) | Last Updated |
|---|---|---|---|---|---|
| 23 Oct 2026 | ₹344 | +₹17 | ₹361.00 | +4.9% | 06:37 PM |
| 22 Oct 2026 | ₹344 | +₹17 | ₹361.00 | +4.9% | 06:32 PM |
| 21 Oct 2026 | ₹344 | +₹19 | ₹363.00 | +5.5% | 06:34 PM |
| 20 Oct 2026 | ₹344 | +₹24 | ₹368.00 | +7.0% | 06:32 PM |
| 19 Oct 2026 | ₹344 | +₹24 | ₹368.00 | +7.0% | 04:37 AM |
| 18 Oct 2026 | ₹344 | +₹23 | ₹367.00 | +6.7% | 11:59 AM |
| 18 Oct 2026 | ₹344 | +₹29 | ₹373.00 | +8.4% | 02:40 PM |
| 17 Oct 2026 | ₹344 | +₹18 | ₹362.00 | +5.2% | 04:30 AM |
| 16 Oct 2026 | ₹344 | +₹38 | ₹382.00 | +11.0% | 04:28 AM |
| 15 Oct 2026 | ₹344 | +₹46 | ₹390.00 | +13.4% | 04:41 AM |
| 14 Oct 2026 | ₹344 | +₹38 | ₹382.00 | +11.0% | 04:29 AM |
| 13 Oct 2026 | ₹344 | +₹35 | ₹379.00 | +10.2% | 04:23 AM |
| 12 Oct 2026 | ₹344 | +₹35 | ₹379.00 | +10.2% | 05:39 AM |
| 11 Oct 2026 | ₹344 | +₹40 | ₹40.00 | +11.6% | 02:51 PM |
| 10 Oct 2026 | ₹344 | ₹0 | ₹0.00 | 0.0% | 03:02 PM |
| 17 Apr 2026 | ₹344 | ₹0 | ₹0.00 | 0.0% | 10:25 AM |
Subscription Details (No. of Shares)Live Demand Book
| Category | Shares Offered | Shares Applied | Subscription Demand |
|---|---|---|---|
| QIB | 27,14,424 | 9,41,79,804 | 0x |
| NIB | 20,35,817 | 2,98,12,072 | 0x |
| RETAIL | 47,50,241 | 1,44,31,531 | 0x |
| EMPLOYEES | 2,50,000 | 92,880 | 0x |
| HNIs(10L +) | 13,57,212 | 2,22,12,725 | 0x |
| HNIs (2-10L) | 6,78,606 | 75,99,347 | 0x |
Day Wise Subscription Details
| Day | Date | QIB (x) | NII (x) | Retail (x) | Total (x) |
|---|---|---|---|---|---|
| Day 1 | - | 0x | 0x | 0x | 0x |
| Day 2 | - | 0x | 0x | 0x | 0x |
| Day 3 | - | 0x | 0x | 0x | 0x |
IPO Reservation Breakup
| Investor Category | Shares Offered | Allocation (%) |
|---|---|---|
| Anchor | 40,71,634 | 29.46% |
| QIB | 27,14,424 | 19.64% |
| HNI | 20,35,817 | 14.73% |
| RETAIL | 47,50,241 | 34.37% |
| Employee | 2,50,000 | 1.81% |
Official IPO Documents & Filings
Red Herring Prospectus (RHP)
Complete issue guidelines, risks, financials, and company profile.
Draft Red Herring (DRHP)
Initial draft submitted to SEBI before price discovery.
Sahajanand Medical Technologies Limited IPO Review & FAQ
Everything you need to know about IPO GMP, Kostak, and listing expectations.
As of today, Sahajanand Medical Technologies Limited IPO Grey Market Premium (GMP) is trading at ₹17 per share. With an issue cap price of ₹344, the expected listing price is ₹361 (+4.9% gain).
UPCOMING15 OCT
OPEN15 OCT
CLOSE19 OCT
LISTED23 OCT
Quick NavigationAuto-Synced
Issue Key Information
Allotment StatusPrice Band₹327 - ₹344
Issue Cap Price₹344
Market Lot Size43 Shares
Min Retail Outlay₹14,061
Total Issue Size₹475.48 Cr
Listing ExchangesNSE, BSE
RegistrarLink Intime India Private Limited
IPO Lot & Return Calculator
1 Lot(s)
Total Shares Applied:43 shares
Required Investment (At Cap):₹14,792
Expected Listing Gain (@ GMP):+₹731
Estimated Portfolio Value:₹15,523